H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Oncolytics Biotech today and set a price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio’s rating is based on Oncolytics Biotech achieving a significant regulatory milestone with the FDA, which has endorsed the pivotal Phase 3 trial design for pelareorep in treating first-line metastatic pancreatic ductal adenocarcinoma. This endorsement includes approval of the survival-based primary endpoint and the flexibility to conduct either a two-arm or three-arm study. Such alignment with the FDA reduces regulatory risks and strengthens confidence in pelareorep’s potential across multiple indications, including squamous cell carcinoma of the anal canal and KRAS-mutant metastatic colorectal cancer.
The FDA’s agreement on the trial’s core components, including the study population, endpoints, and treatment schedules, further de-risks the program. The agency’s acceptance of an interim analysis strategy and the potential for accelerated approval also positions pelareorep as a leading candidate in a field lacking approved immuno-oncology options. These factors collectively underpin Trucchio’s Buy rating, reflecting a positive outlook on Oncolytics’ strategic direction and potential market impact.
Trucchio covers the Healthcare sector, focusing on stocks such as Aligos Therapeutics, Precision BioSciences, and Altimmune. According to TipRanks, Trucchio has an average return of 25.6% and a 52.16% success rate on recommended stocks.
In another report released on November 17, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.